Netherlands· NL-83eec9130e45
Pyrukynd 5 mg, filmomhulde tabletten
A mitapivat product containing mitapivat 0,5-sulfaat 1,5-water, registered in Netherlands by Agios Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Mitapivat is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AX04 (mitapivat), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Mitapivat · ATC B06AX04
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MITAPIVAT 0,5-SULFAAT 1,5-WATER
- Manufacturer
- Agios Netherlands B.V.
- Country
- Netherlands (NL)
- ATC code
- B06AX04
- ATC class
- Mitapivat
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1662
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mitapivat in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesPYRUKYNDAgios Pharmaceuticals, Inc.
- CzechiaPYRUKYNDAgios Netherlands B.V., Amsterdam
- BelgiumPyrukynd 5 mgAgios Netherlands
- FinlandPyrukyndAgios Netherlands B.V.
- IrelandPyrukynd 5 mg film-coated tabletsAgios Netherlands B.V.
- IcelandPyrukyndAgios Netherlands B.V.
- PolandPyrukyndAgios Netherlands B.V.
- SwedenPyrukynd 5 mg Filmdragerad tablettAgios Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pyrukynd
- Liechtenstein · Pyrukynd
- Norway · Pyrukynd
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1aa9147b-8a55-464a-80ef-9621fd8fd9db GET /v1/drugs/1aa9147b-8a55-464a-80ef-9621fd8fd9db?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/pyrukynd-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Mitapivat",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128597",
"excipients": [
"AMMONIA (E 527)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"GLYCEROLTRIACETAAT (E 1518)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE ZWART (E 172)",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"LACTOSE 1-WATER",
"MANNITOL (D-) (E 421)",
"NATRIUMSTEARYLFUMARAAT",
"PROPYLEENGLYCOL (E 1520)",
"SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"MITAPIVAT 0,5-SULFAAT 1,5-WATER"
],
"leaflet_url": null,
"authorised_at": "2022/11/09",
"procedure_number": "EMEA/H/C/005540",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1662",
"additional_monitoring": "N"
}See everything about mitapivat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.